Q4 2024 Orthofix Medical Inc Earnings Call Transcript
Key Points
- Orthofix Medical Inc (OFIX) achieved a record-setting year in 2024, with significant growth across all major product lines.
- The company reported an 8% year-over-year growth in net sales for Q4 2024, reaching $215.7 million.
- Orthofix's Bone Growth Therapy business experienced a record year, with a 9% growth in Q4, driven by new customer conversions.
- The company successfully expanded its U.S. spinal fixation business, growing more than double the market growth rate.
- Orthofix improved its financial strength with $21 million in positive free cash flow in the second half of 2024 and negotiated a new term loan with better terms.
- Orthofix Medical Inc (OFIX) decided to discontinue the M6-C and M6-L artificial disc product lines, which have been a headwind to the company's top-line growth.
- The company faces a $4 million negative impact from foreign currency fluctuations in 2025.
- Orthofix anticipates variability in growth rates due to the timing and volume of stocking distributor and tender orders.
- The company expects Q1 2025 to be slightly below the low end of its full-year net sales growth guidance due to timing issues.
- Orthofix is sunsetting non-core orthopedic products in the U.S. that do not align with its strategic focus, which may impact short-term sales.
Thank you for standing by. My name is Jeannie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Orthofix Q4 2024 earnings call.
All lines have been placed on mute to prevent any background noise.
After the speaker's remarks, there will be a question-and-answer session.
(Operator Instructions)
Thank you. I would now like to turn the call over to Julie Dewey. Please go ahead.
Thank you, operator, and good morning, everyone.
Welcome to Orthofix fourth quarter 2024 earnings call. We appreciate you joining us. I'm Julie Dewey, Orthofix Chief IR and Communications Officer. Joining me on the call today are President and Chief Executive Officer, Massimo Calafiore; and Chief Financial Officer, Julie Andrews. Before we get started, please note that our earnings release and the supplemental presentation accompanying this call are available on the events and presentations page of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
